Third, Vertex still has an exciting pipeline in CF and elsewhere. For instance, the company's late-stage candidate for APOL-1 ...

Vertex Pharmaceuticals (VRTX) closed at $468.41 in the latest trading session, marking a +1.64% move from the prior day. This change outpaced the S&P 500's 0.3% loss on the day. Meanwhile, the Dow ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

This was the stock's third consecutive day of losses.

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Vertex Pharmaceuticals ...

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

Over the past decade, Vertex Pharmaceuticals (NASDAQ: VRTX) has delivered above-average returns. The secret behind the biotech's success isn't much of a secret. The drugmaker developed and ...

Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals Share Price Analysis Shares of Vertex Pharmaceuticals were trading at $498.86 as of May 01. Over the last 52-week period, shares are up 24.51%.

Vertex Pharmaceuticals (NASDAQ: VRTX), the Boston based Pharma giant with an almost monopolistic share of the Cystic Fibrosis treatment market, announced its Q2 2024 earnings at the beginning of ...

The stock price of Vertex Pharmaceuticals has seen an 8.1% drop over the last five trading days, after the company announced that it will discontinue the clinical trials for VX-864, an ...